Cetamolol, (S)- | 116679-71-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Cetamolol, (S)-
• 英文别名: 2-[2-[(2S)-3-(tert-butylamino)-2-hydroxypropoxy]phenoxy]-N-methylacetamide
• CAS: 116679-71-1
• 化学式: C₁₆H₂₆N₂O₄
• 分子量: 310.39
• InChiKey: UWCBNAVPISMFJZ-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  79.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Prodrugs containing novel bio-cleavable linkers
  申请人：Satyam Apparao

  公开号：US20060046967A1

  公开（公告）日：2006-03-02

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了公式(I)的化合物或其药用可接受的盐。本发明还提供了包含一个或多个公式I的化合物或其中间体以及一个或多个药用可接受的载体、车辆或稀释剂的药物组合物。本发明进一步提供了包括制备方法和使用方法在内的前药，包括释放一氧化氮的前药、双前药和相互前药，由公式I的化合物组成。
• [EN] COMBINATION OF (S)-AMLODIPINE AND A BETA-BLOCKER, AND METHODS FOR REDUCING HYPERTENSION<br/>[FR] COMBINAISON DE (S)-AMLODIPINE ET D'UN BETABLOQUANT, ET PROCEDES POUR LA REDUCTION DE L'HYPERTENSION
  申请人：SEPRACOR INC

  公开号：WO2005099699A1

  公开（公告）日：2005-10-27

  One aspect of the present invention relates to pharmaceutical compositions comprising optically pure (S)-amlodipine and a beta-blocker. In a preferred embodiment, the beta-blocker is atenolol or bisprolol. Another aspect of the present invention relates to pharmaceutical compositions consisting essentially of at least one pharmaceutically acceptable carrier, optically pure (S)-amlodipine and a beta-blocker. In a preferred embodiment, the beta-blocker is atenolol or bisoprolol. The pharmaceutical compositions of the invention are useful, e.g., in the treatment of hypertension. In addition, the present invention also relates to a method of treating a patient suffering from hypertension or a related cardiac disorder, comprising co-administering to a patient in need thereof a therapeutically effective amount of optically pure (S)-amlodipine and a beta-blocker. In certain embodiments of the compositions and methods, said optically pure (S)-amlodipine is optically pure (S)-amlodipine malate, or a polymorph, pseudopolymorph or solvate thereof.

  本发明的一个方面涉及包含光学纯（S）-氨氯地平和β受体阻断剂的制药组合物。在一个首选实施例中，β受体阻断剂为阿托伐他汀或比索洛尔。本发明的另一个方面涉及基本上由至少一种药用载体、光学纯（S）-氨氯地平和β受体阻断剂组成的制药组合物。在一个首选实施例中，β受体阻断剂为阿托伐他汀或比索洛尔。本发明的制药组合物可用于治疗高血压等疾病。此外，本发明还涉及一种治疗患有高血压或相关心脏疾病的患者的方法，包括向需要的患者共同给予光学纯（S）-氨氯地平和β受体阻断剂的治疗有效量。在某些组合物和方法的实施例中，所述的光学纯（S）-氨氯地平为光学纯（S）-氨氯地平苹果酸盐，或其多晶形、伪多晶形或溶剂化合物。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• [EN] NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES<br/>[FR] SELS DE NITRATE DE MEDICAMENTS ANTI-HYPERTENSEURS
  申请人：NICOX S.A.

  公开号：WO1999067231A1

  公开（公告）日：1999-12-29

  (EN) Nitric acid salts with medicines having an antihypertensive activity.(FR) L'invention concerne des sels d'acide nitrique de médicaments possédant une activité antihypertensive.

  (EN) Nitric acid salts with medicines having an antihypertensive activity. 翻译为：具有降压活性的药物的硝酸盐。 (FR) L'invention concerne des sels d'acide nitrique de médicaments possédant une activité antihypertensive. 翻译为：具有降压活性的药物的硝酸盐。
• Compositions and methods to effect the release profile in the transdermal administration of active agents
  申请人：——

  公开号：US20020004065A1

  公开（公告）日：2002-01-10

  Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.

  本发明涉及一种用于经皮递送活性药剂的组合物和方法，该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂，包括一种药学上可接受的粘合基质和一种聚合物塑料材料，该聚合物塑料材料对活性药剂具有释放速率调节作用。